Analysis of refractory ascites components of patients with ovarian cancer, fallopian tube cancer and peritoneal cancer, and examination of influence by Cell-free and Concentrated Ascites Reinfusion Therapy (CART)
Not Applicable
- Conditions
- ovarian cancer, fallopian tube cancer and peritoneal cancer
- Registration Number
- JPRN-UMIN000034893
- Lead Sponsor
- Iwate Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with fever and suspected of detecting endotoxin 2. Highly immunocompromised patients such as bone marrow transplantation 3. Patients with severe heart failure, renal failure, liver failure combined 4. Patients complicated with bacterial peritonitis 5. Serious liver disorder patients with overt jaundice 6. Patients used Bevacizumab within 6 weeks 7. Patients using steroids for mitigation purposes 8. Patients participating in other trials and clinical studies 9. Patients who are determined to be disqualified by a principal investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cytokine profile of ascites, ascites after filtration and concentration, and serum.
- Secondary Outcome Measures
Name Time Method A) Evaluation of QOL in pre-post CART B) Changes in cytokine levels of ascites filtered and concentrated ascites in storage at 4 degrees C) Blood test values of pre-post CART D) Adverse events